← Back to Search

Vaccine

20-valent pneumococcal conjugate vaccine for Pneumococcal Diseases

Phase 3
Waitlist Available
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within 7 days after dose 4
Awards & highlights

Study Summary

This trial will test a new vaccine in infants to see if it is safe and tolerated well.

Eligible Conditions
  • Pneumococcal Diseases

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within 7 days after dose 4
This trial's timeline: 3 weeks for screening, Varies for treatment, and within 7 days after dose 4 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of Participants With AEs From Dose 4 to 1 Month After Dose 4
Percentage of Participants With Adverse Events (AEs) From Dose 1 to 1 Month After Dose 3
Percentage of Participants With Local Reactions Within 7 Days After Dose 1
+9 more

Side effects data

From 2022 Phase 3 trial • 1511 Patients • NCT04379713
88%
Irritability (IRRITABILITY)
81%
Hypersomnia (INCREASED SLEEP)
61%
Injection site pain (PAIN)
55%
Decreased appetite (DECREASED APPETITE)
46%
Injection site erythema (REDNESS)
37%
Injection site swelling (SWELLING)
34%
Pyrexia (FEVER)
6%
Upper respiratory tract infection
1%
Bronchiolitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
20vPnC
13vPnC

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: 20-valent pneumococcal conjugate vaccineExperimental Treatment1 Intervention
Pneumococcal conjugate vaccine
Group II: 13-valent pneumococcal conjugate vaccineActive Control1 Intervention
Pneumococcal conjugate vaccine
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
20-valent pneumococcal conjugate vaccine
2022
Completed Phase 3
~6190

Find a Location

Who is running the clinical trial?

PfizerLead Sponsor
4,570 Previous Clinical Trials
10,914,515 Total Patients Enrolled
26 Trials studying Pneumococcal Diseases
105,828 Patients Enrolled for Pneumococcal Diseases
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,476 Previous Clinical Trials
8,090,710 Total Patients Enrolled
26 Trials studying Pneumococcal Diseases
105,828 Patients Enrolled for Pneumococcal Diseases

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants
2020. "20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04379713.
~307 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top